HPV疫苗进入稳健成长期，关注带疱疫苗放量

Investment Rating - The investment rating for the company is "Outperform" [18]. Core Views - The company's 2023 revenue reached 52.918 billion RMB, a year-on-year increase of 38.3%, while the net profit attributable to the parent company was 8.070 billion RMB, growing by 7.0% [4][7]. - The company plans to distribute a cash dividend of 8.0 RMB for every 10 shares [4]. - The revenue for Q1 2024 was 11.396 billion RMB, reflecting a 2.0% year-on-year growth, but net profit decreased by 28.3% to 1.458 billion RMB due to changes in revenue structure affecting gross margin [4][14]. Financial Performance Summary - Revenue Growth: - 2022: 38.264 billion RMB - 2023: 52.918 billion RMB (38.3% growth) - 2024E: 60.286 billion RMB (13.9% growth) - 2025E: 68.225 billion RMB (13.2% growth) [7][10]. - Net Profit: - 2022: 7.539 billion RMB - 2023: 8.070 billion RMB (7.0% growth) - 2024E: 9.477 billion RMB (17.4% growth) - 2025E: 10.980 billion RMB (15.9% growth) [7][10]. - Earnings Per Share: - 2022: 3.15 RMB - 2023: 3.37 RMB - 2024E: 3.96 RMB - 2025E: 4.59 RMB [7][10]. - Valuation Ratios: - P/E Ratio: 2023A: 10.9, 2024E: 9.3, 2025E: 8.0 - P/B Ratio: 2023A: 2.8, 2024E: 2.3, 2025E: 1.9 - EV/EBITDA: 2023A: 8.7, 2024E: 7.2, 2025E: 6.1 [7][10]. Business Development Trends - The HPV vaccine business is entering a stable growth phase, with agency product revenue of 51.885 billion RMB in 2023, up 48.35%, while self-produced product revenue fell by 68.70% [8]. - The company is expected to increase the sales proportion of the 9-valent HPV vaccine, which is anticipated to be a major contributor to future performance [8]. - The company has begun to roll out the GSK shingles vaccine, with significant sales expected in Q2 2024 [8]. - R&D investment reached 1.345 billion RMB in 2023, a 20.82% increase, with several products in various stages of clinical trials [8].